Anselamimab clinical trials
Also written CAEL-101.
How each study uses anselamimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the anselamimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2020 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 1
Studies
Open first, then newest update. How each study uses anselamimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue InvolvementNot yet recruitingEarly Phase 1Stanford UniversityNCT07615270Written as Anselamimab
- A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)Active, not recruitingPhase 3Alexion Pharmaceuticals, Inc.NCT04504825Written as CAEL-101
- A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)Active, not recruitingPhase 3Alexion Pharmaceuticals, Inc.NCT04512235Written as CAEL-101
- A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL AmyloidosisCompletedPhase 2Alexion Pharmaceuticals, Inc.NCT04304144Written as CAEL-101
- Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL AmyloidosisCompletedPhase 1Alexion Pharmaceuticals, Inc.NCT02245867Written as Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4
Codes
What other systems call anselamimab · ClinicalTrials.gg INT018033
- UNII (FDA) TL94QQ5RTWANSELAMIMABOne source FDA
- NCI Thesaurus C117241AnselamimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | TL94QQ5RTW | ANSELAMIMAB | One source FDA |
| NCI Thesaurus | C117241 | Anselamimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.